People march through downtown Detroit, Michigan on Saturday, April 19, 2025 Dominic Gwinn | Afp | Getty Images Social Security is the nation's largest social insurance program, making payments to approximately 75 million Americans every month. Yet the program faces an imminent funding shortfall . Social Security's trust fund for retirement benefits may run out in 2032, which could prompt an across...
People march through downtown Detroit, Michigan on Saturday, April 19, 2025 Dominic Gwinn | Afp | Getty Images Social Security is the nation's largest social insurance program, making payments to approximately 75 million Americans every month. Yet the program faces an imminent funding shortfall . Social Security's trust fund for retirement benefits may run out in 2032, which could prompt an across-the-board benefit cut, according to projections from the Social Security Administration and Congressional Budget Office . Social Security has been on the brink of funding cuts before. In 1983, when the last major reforms to the program were enacted, Social Security was just months away from not being able to pay full benefits. At that time, lawmakers voted on bipartisan legislation that included taxes on benefit income and gradual increases to the retirement age to restore the program's solvency. With the program facing looming trust fund depletion dates, Washington leaders will need to come together again to shore up the program's funding — or risk imminent benefit cuts if the program can't pay benefits as promised. During a March 25 Senate budget committee hearing focused on the "path forward" for the program, some leaders said Congress is up to the task. "We can do this," Sen. Sheldon Whitehouse, D-R.I., said of addressing the program's shortfall. "It's actually not all that hard or complicated. And the sooner we do it, the better off everyone will be." Read more CNBC personal finance coverage Social Security needs more money. The question is, who will pay? Should you 'buy the dip' amid the latest stock market volatility? What experts say Boston Fed: Credit card APRs have 'economically meaningful' impact on spending Retirement saver protection rule has died — for the second time More than 7 million student loan borrowers face deadline to leave SAVE plan Department of Labor proposes rules for including alternative assets in 401(k)s 31.5% of car buyers underwater on trade...
eclipse_images/E+ via Getty Images Investment Overview News has broken this morning that Eli Lilly and Company ( LLY ), the world's largest Pharmaceutical company by market cap valuation - presently $837bn (down from >$1 trillion dollars earlier this year), is set to acquire Centessa Pharmaceuticals plc ( CNTA ) in a deal valued at ~$6.3bn, or $38 per share, with a contingent value right ("CVR") a...
eclipse_images/E+ via Getty Images Investment Overview News has broken this morning that Eli Lilly and Company ( LLY ), the world's largest Pharmaceutical company by market cap valuation - presently $837bn (down from >$1 trillion dollars earlier this year), is set to acquire Centessa Pharmaceuticals plc ( CNTA ) in a deal valued at ~$6.3bn, or $38 per share, with a contingent value right ("CVR") attached that could provide an additional potential aggregate equity value of ~$1.5 billion, or $9 per share. In a press release issued today, Centessa discusses its business as follows: Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton (formerly ORX750) has demonstrated a potential best-in-class profile in Phase 2a clinical studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions. Analysis - Why Centessa, Why Now? Eli Lilly stock is up >1,100% on a 10-year basis, and >375% on a five-year basis - phenomenal returns for a "Big Pharma" company and primarily built on the runaway success of its drug molecule tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mimetic, approved to treat Type 2 diabetes as Mounjaro, and Obesity as Zepbound. These two products earned a combined ~$37bn last year - more than any other drug molecule - however Lilly also boasts a neuroscience division which earned revenues of ~$1.4bn last year, thanks to products such as depression med Cymbalta - $63m revenues in 2025, migraine therapies Emgality, $748m, and Reywow, $38m, plus Alzheimer's therapy Kisunla -...
J Studios/DigitalVision via Getty Images Introduction & Investment Thesis When I last wrote about MongoDB ( MDB ), I compared its positioning and operational rigor it demonstrated over the prior two quarters, similar to that of Palantir ( PLTR ), that allowed the company to shield itself from the “AI eating SaaS” narrative while earning a rich multiple. Unfortunately, with Atlas decelerating in Q4...
J Studios/DigitalVision via Getty Images Introduction & Investment Thesis When I last wrote about MongoDB ( MDB ), I compared its positioning and operational rigor it demonstrated over the prior two quarters, similar to that of Palantir ( PLTR ), that allowed the company to shield itself from the “AI eating SaaS” narrative while earning a rich multiple. Unfortunately, with Atlas decelerating in Q4 FY26 , after three quarters of acceleration, along with tepid forward guidance from management, investor sentiment quickly soured on the stock, sending it 30% lower after earnings. What further aggravated the whole situation was management commentary on the earnings call saying that AI is not a material revenue driver while not providing a timeline as to when they expect an inflection. In this post, I will explain both the “good” and the “bad” from the latest earnings report and will discuss whether the post-earnings dip of 30% is worth buying, as the risk-reward looks attractive, especially if the company can surprise investors to the upside in the coming quarters given its fundamental positioning in the AI stack. A High-Level Overview of MongoDB’s Q4 FY26 MongoDB reported their Q4 FY26 earnings at the start of last month, where revenue growth accelerated compared to the previous quarter at 26.75% YoY to $695.1M, with non-GAAP operating income margin expanding 200 basis points year-over-year to 23%. With both revenue and earnings beating estimates, management attributed the strength to both Atlas and non-Atlas revenue, which grew 29% YoY, contributing 72% of total revenue, while non-Atlas also grew 20% YoY, their best quarter in the last two years. For the full year, the company ended with 65,200 customers, growing 60% YoY. But it is their progress upmarket that is worth taking notice of. In Q4, the number of customers with $100K+ and $1M+ ARR (Annual Recurring Revenue) grew 17% and 26% YoY to 2,799 and 402, respectively. What management also noted was that ARR for these ...
Palisade Bio ( PALI ) fell for the second consecutive session on Tuesday after initial data from an early-stage trial for its lead asset PALI-2108 in fibrostenotic Crohn’s disease (FSCD), a severe form of Crohn’s disease characterized by the formation of fibrotic tissue in the bowel. Citing two weeks of data from a Phase 1b clinical study, Palisade ( PALI ) said that the once-daily oral therapy le...
Palisade Bio ( PALI ) fell for the second consecutive session on Tuesday after initial data from an early-stage trial for its lead asset PALI-2108 in fibrostenotic Crohn’s disease (FSCD), a severe form of Crohn’s disease characterized by the formation of fibrotic tissue in the bowel. Citing two weeks of data from a Phase 1b clinical study, Palisade ( PALI ) said that the once-daily oral therapy led to endoscopic response rates roughly in line with those caused by risankizumab and upadacitinib, CD therapies marketed by AbbVie ( ABBV ) as Skyrizi and Rinvoq, respectively. The Denver, Colorado-based biotech added that there were no serious adverse events and the experimental therapy was well tolerated among five patients with FSCD and confirmed ileal stenosis who enrolled in the study. According to Palisade ( PALI ), data support the continued clinical advancement of PALI-2108, and it plans to launch a Phase 2 study to test the oral PDE4 inhibitor prodrug in moderate to severe Crohn’s disease. More on Palisade Bio Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio
KENNEDY SPACE CENTER, Fla.—This will be the third time I have observed NASA’s Orion spacecraft take flight. But with this one, for the first time, am I genuinely hopeful about the future of the space agency and its plans to build a station on the surface of the Moon. The two previous flights, in 2014 and 2022, both felt hollow. NASA, an aging bureaucracy, has repeatedly sought to recapture its fad...
KENNEDY SPACE CENTER, Fla.—This will be the third time I have observed NASA’s Orion spacecraft take flight. But with this one, for the first time, am I genuinely hopeful about the future of the space agency and its plans to build a station on the surface of the Moon. The two previous flights, in 2014 and 2022, both felt hollow. NASA, an aging bureaucracy, has repeatedly sought to recapture its fading glory while also looking toward a supposedly brighter future. Agency leaders would say things like this, from then-NASA Administrator Charlie Bolden, after the first Orion launch in 2014: “This is the beginning of the Mars era.” It wasn’t. No one who was paying attention believed it. But it was the kind of thing you had to say, I guess. Read full article Comments
In this article SNAP UBER META XYZ Follow your favorite stocks CREATE FREE ACCOUNT Evan Spiegel, CEO of Snap Inc., speaks onstage during the Snap Partner Summit 2023 at Barker Hangar on April 19, 2023 in Santa Monica, California. Joe Scarnici | Getty Images Entertainment | Getty Images Shares of Snap climbed 13% Tuesday after shareholder Irenic Capital Management sent a letter to CEO Evan Spiegel ...
In this article SNAP UBER META XYZ Follow your favorite stocks CREATE FREE ACCOUNT Evan Spiegel, CEO of Snap Inc., speaks onstage during the Snap Partner Summit 2023 at Barker Hangar on April 19, 2023 in Santa Monica, California. Joe Scarnici | Getty Images Entertainment | Getty Images Shares of Snap climbed 13% Tuesday after shareholder Irenic Capital Management sent a letter to CEO Evan Spiegel outlining changes that could increase the stock's value by almost 600%. "Snap should not continue doing what it has been doing. It's not working," Irenic wrote in its letter, published on savesnapnow.com alongside a presentation of recommendations. According to the letter, Irenic Capital manages about $2.5 billion in assets and owns about 2.5% of Snap's Class A shares . The recommendations, titled "6 Steps to 7X," aim to increase Snap's stock price from $3.93 to over $26 per share. Irenic's recommendations include shutting down or spinning off Specs, the company's augmented reality glasses unit. The unit was announced to be a wholly owned subsidiary of Snap in January. Referencing previous layoffs from Uber , Meta and Block , Irenic said Snap should use artificial intelligence more heavily to cut 1,000 employees, or 21% of its workforce. "AI can and should replace many existing roles," Irenic wrote under 'rationalize costs,' the company's second recommendation. Read more CNBC tech news Nebius unveils plans to build one of Europe's largest AI factories as region scrambles for compute Micron shares have cratered 30% since the memory maker reported blowout earnings Delaware judge reassigns Elon Musk cases after accusation of bias Palo Alto shares pop as CEO Nikesh Arora buys stock for first time in years "Snap welcomes input from all shareholders and regularly engages with investors on strategy, capital allocation, and governance," Snap chairman Michael Lynton told CNBC in a statement. "We've taken steps to improve performance, strengthen free cash flow, and offset dilution, a...
ismagilov Shares of Marvell Technology ( MRVL ) surged 11.3% Tuesday afternoon following NVIDIA’s ( NVDA ) announcement of a $2B investment and an expanded strategic partnership. The collaboration will integrate Marvell’s capabilities into NVIDIA’s AI infrastructure ecosystem through NVLink Fusion, reinforcing Marvell’s positioning within next-generation data center architecture. The move also lif...
ismagilov Shares of Marvell Technology ( MRVL ) surged 11.3% Tuesday afternoon following NVIDIA’s ( NVDA ) announcement of a $2B investment and an expanded strategic partnership. The collaboration will integrate Marvell’s capabilities into NVIDIA’s AI infrastructure ecosystem through NVLink Fusion, reinforcing Marvell’s positioning within next-generation data center architecture. The move also lifted a broad range of exchange-traded funds with meaningful exposure to Marvell Technology. ETFs such as the Direxion Daily MRVL Bull 2X ETF ( MRVU ) and several semiconductor-focused funds posted notable gains as the stock rallied. Marvell remains widely held across the ETF landscape, with 292 funds collectively owning roughly 145.6M shares, underscoring its growing importance within AI-driven investment themes. Outlined below are the 10 ETFs with the largest portfolio allocations towards shares of MRVL: Direxion Daily MRVL Bull 2X ETF ( MRVU ), 10.73% allocation. Fidelity Disruptive Technology ETF ( FDTX ), 5.63% allocation. iShares MSCI Global Sustainable Development Goals ETF ( SDG ), 5.11% allocation. U.S. Global Technology and Aerospace & Defense ETF ( WAR ), 5.07% allocation. iShares Semiconductor ETF ( SOXX ), 5.04% allocation. Invesco PHLX Semiconductor ETF ( SOXQ ), 5.03% allocation. VanEck Fabless Semiconductor ETF ( SMHX ), 4.99% allocation. First Trust Nasdaq Semiconductor ETF ( FTXL ), 4.94% allocation. TCW Transform Systems ETF ( PWRD ), 4.91% allocation. iShares Future AI & Tech ETF ( ARTY ), 4.88% allocation. More on markets Treasury yields surge in March, posting the biggest monthly jump since 2024 Wells Fargo lowers its year-end S&P 500 target from 7,800 to 7,300 S&P 500 is on pace for its worst month since 2022 as broad selloff deepens Selling pressure intensifies as now nearly 300 of the S&P 500 names trade lower in 2026 Recession odds in 2026 jump to nearly 40% on prediction markets
Iran’s Islamic Revolutionary Guard Corps issued a warning to several major international corporations, alleging their involvement in operations conducted by the U.S. and Israel against Iran and said they would be treated as “legitimate targets.” The Revolutionary Guard on Tuesday accused companies including Apple, Oracle, Palantir, Microsoft, Alphabet and JPMorgan Chase of contributing to the plan...
Iran’s Islamic Revolutionary Guard Corps issued a warning to several major international corporations, alleging their involvement in operations conducted by the U.S. and Israel against Iran and said they would be treated as “legitimate targets.” The Revolutionary Guard on Tuesday accused companies including Apple, Oracle, Palantir, Microsoft, Alphabet and JPMorgan Chase of contributing to the planning and execution of attacks that resulted in the deaths of Iranian citizens. In what it labeled “Statement No. 51,” the Revolutionary Guard asserted American information and communications technology and artificial intelligence firms play a central role in identifying and tracking targets.
An online government portal to provide refunds on tariffs struck down by the US Supreme Court will handle claims for about 63% of 53 million import entries at issue when it first launches, according to a new court filing. A Trump administration official with US Customs and Border Protection told a judge in a declaration submitted Tuesday that the government won’t be able to process refund demands ...
An online government portal to provide refunds on tariffs struck down by the US Supreme Court will handle claims for about 63% of 53 million import entries at issue when it first launches, according to a new court filing. A Trump administration official with US Customs and Border Protection told a judge in a declaration submitted Tuesday that the government won’t be able to process refund demands for the remaining one-third of entries right away, and didn’t offer a specific time frame for rolling out later phases. The agency has previously told a judge on the US Court of International Trade that the US is working to have the first phase of the new refund system ready by mid-April. Read More: Judge Orders US to Stop Calculating Importers’ IEEPA Tariffs The government has estimated that importers paid more than $166 billion in tariffs under President Donald Trump’s executive orders that a majority of justices declared unlawful in February. Officials have committed to paying interest on any refunds as well. The first phase of the administration’s refund process will be able to accept claims for tariffs that haven’t become final yet, according to the government. Tariffs typically become “final” more than a year after goods enter the country, although so-called “informal” tariffs for low-value shipments can reach that status sooner. Lawyers for companies that paid Trump’s contested tariffs recently raised concerns in court about refund delays for these “final” duties. The lawyers said that more import entries will keep automatically hitting the final stage unless companies file protests — a potentially costly and time-consuming enterprise, they argued. The US trade court has put Judge Richard Eaton in charge of managing the tariff refund litigation. Earlier this month, Eaton ordered the government to begin the process of recalculating tariffs to remove the levies struck down by the Supreme Court, but his initial rulings didn’t cover “final” tariffs. After companies raise...
Amazon stock is down about 11% year-to-date, but Wall Street is starting to lean more bullish again. The shift comes as AWS growth reaccelerates, driven by strong demand for AI workloads. At the same time, Amazon’s advertising business continues to scale into a larger profit driver, giving the ...
Amazon stock is down about 11% year-to-date, but Wall Street is starting to lean more bullish again. The shift comes as AWS growth reaccelerates, driven by strong demand for AI workloads. At the same time, Amazon’s advertising business continues to scale into a larger profit driver, giving the ...
Many countries in Europe have called the conflict illegal, with some blocking Israeli and US planes from moving weapons through their airspace Donald Trump has launched a tirade against European countries that refused to join his war against Iran, calling out the UK and France, as transatlantic relations soured from the spiralling conflict that has wreaked havoc on the global economy. On his Truth...
Many countries in Europe have called the conflict illegal, with some blocking Israeli and US planes from moving weapons through their airspace Donald Trump has launched a tirade against European countries that refused to join his war against Iran, calling out the UK and France, as transatlantic relations soured from the spiralling conflict that has wreaked havoc on the global economy. On his Truth Social website, the US president told governments worried about fuel prices to “go get your own oil” by force from the Gulf, comments that sent oil prices even higher. Continue reading...